Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.52 |
| ▸ | DUSP4 | Q13115 | 1/20 | 0.52 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391203 | 1.00 | PTGES (0.54) | PTGESPTPN1MTORPTP4A3DUSP4 | |
| SCHEMBL13345210 | 0.85 | PLK1 (0.65) | PTGESMTORPTP4A3DUSP4PTP4A1 | |
| SCHEMBL3391172 | 0.80 | PTGES (0.53) | PTGESMTORPTP4A3DUSP4PTP4A1 | |
| SCHEMBL3391167 | 0.80 | PTGES (0.53) | PTGESMTORPTP4A3DUSP4PTP4A1 | |
| SCHEMBL23036942 | 0.79 | MTOR (0.59) | PTGESMTORPARP1PTGS2 | |
| SCHEMBL3393009 | 0.76 | MTOR (0.56) | PTGESMTORPARP1PTGS2 | |
| SCHEMBL3389983 | 0.76 | PTGES (0.61) | PTGESPTP4A3DUSP4PTP4A1PTGS2 | |
| SCHEMBL3389978 | 0.76 | PTGES (0.61) | PTGESPTP4A3DUSP4PTP4A1PTGS2 | |
| SCHEMBL4035544 | 0.76 | PIK3CG (0.62) | PIK3CG | |
| SCHEMBL4035542 | 0.76 | PIK3CG (0.62) | PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861395-B1 | 5-(1,3-DIARYL-1H-PYRAZOL-4-YLMETHYLENE)-THIAZOLIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTICANCER AGENT | KOREA RES INST CHEM TECH (KR) | 2010-12-29 | — | — | EP | disclosed |
| US-7718681-B2 | 5-(1,3-Diaryl-1H-pyrazol-4-ylmethylene)-thiazolidine,2,4-dione derivatives useful as anticancer agent | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-05-18 | — | — | US | disclosed |
| US-20080275094-A1 | 5-(1,3-Diaryl-1H-Pyrazol-4-1 Methylene)-Thiazolidine-2,4-Dione Derivatives Useful as Anticancer Agent | BARCLAYS BANK PLC (GB) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275094-A1 | 5-(1,3-Diaryl-1H-Pyrazol-4-1 Methylene)-Thiazolidine-2,4-Dione Derivatives Useful as Anticancer Agent | TP53, CDKN1A, API5 | PTGES 3261/4885PTPN1 2922/4885MTOR 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.